Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Block by Block campaign to educate community, reduce impact of diabetes

It started with a simple medical survey in the Humboldt Park neighborhood on Chicago's near Northwest side whose results were reported in the Journal of Epidemiology in 2006.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

Statin use may increase risk of developing benign colorectal tumors: APC trial

Statins did not protect patients against colorectal adenomas, which are benign precursors of colorectal cancer, according to results of a secondary analysis of the Adenoma Prevention with Celecoxib trial. In a population at high-risk for developing these lesions, results of this analysis suggested statin use may increase the risk of developing benign colorectal tumors.

20 Apr 2010

Podiatric physicians recommend conservative treatments to relieve heel pain

Millions of Americans complain of heel pain, which is usually caused by plantar fasciitis. Plantar fasciitis is a condition in which the plantar fascia (ligament that runs from your heel to the toes) becomes inflamed. This condition can be very painful and cause a considerable amount of suffering.

20 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.

19 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

A National Cancer Clinical Trials System For The 21st Century: Reinvigorating The NCI Cooperative Group Program - The "system for conducting cancer clinical trials in the United States is approaching a state of crisis," according to this report on inefficiencies and funding issues faced by the NCI's Clinical Trials Cooperative Group Program - which comprises 10 groups, more than 3,100 institutions, 14,000 investigators and more than 25,000 patients in clinical trials each year.

17 Apr 2010

Study shows beneficial impact of TYSABRI on QoL in MS patients

Biogen Idec and Elan Corporation, plc today announced results from a one-year, longitudinal health outcomes studys 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

17 Apr 2010

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

Governor Edward G. Rendell today announced that $1 million from the American Recovery and Reinvestment Act has been awarded to Pennsylvania to prevent and manage chronic disease in older citizens.

17 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Moving is the best medicine for arthritic pain

The burden of arthritis is greater for African Americans and Hispanics, despite lower prevalence among these groups according to a Centers for Disease Control and Prevention (CDC) report published in the May issue of Preventing Chronic Disease.

16 Apr 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Block by Block campaign to educate community, reduce impact of diabetes

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

Statin use may increase risk of developing benign colorectal tumors: APC trial

Podiatric physicians recommend conservative treatments to relieve heel pain

Homeopathy – Is it a safer and effective alternative?

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

Study shows beneficial impact of TYSABRI on QoL in MS patients

Pennsylvania awarded $1M in Recovery Act funding for managing chronic disease in older citizens

VisEn Medical expands FMT imaging platform

Results of study comparing REMICADE to azathioprine for Crohn's disease published

New nanotechnology biomedical therapy for joint injuries

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Moving is the best medicine for arthritic pain

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in